Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Each year, Nature Biotechnology highlights companies that have received sizeable early-stage funding in the previous year. Indapta Therapeutics is using a subset of natural killer cells found in healthy donors to supercharge monoclonal antibodies to fight cancer and autoimmune disease.
Errors in the US Patent and Trademark Office’s automated program to calculate patent expiration dates could result in hundreds of millions of dollars in added costs to drug prices.
The NIH Applicant Assistance Program represents a new paradigm guiding the design of meaningful policy interventions for increasing equity of participation in scientific grant funding.
The digestive prowess of fungi to decontaminate natural environments from polluting plastics, oil spills, toxic waste and even radiation is gaining traction around the globe.
A physician-scientist exploring the mechanisms and physiological relevance of glycoRNAs talks about being useful, the challenges of running a laboratory, and translating foundational knowledge into products that will benefit people.
There is an ever-growing choice of single-cell and spatial ’omics platforms for industry and academia. The scTrends Consortium provides a brief historical overview of the established platforms and companies, revealing market trends and presenting possible angles for how technologies may differentiate themselves.
Biotechs are equipping CAR-T cells to destroy B cells — not to treat blood cancers, but to take on multiple sclerosis and a raft of autoimmune disorders.